Home > Healthcare > Pharmaceuticals > Finished Drug Form > Triptorelin Market

Triptorelin Market Size

  • Report ID: GMI5427
  • Published Date: Feb 2023
  • Report Format: PDF

Triptorelin Market Size

Triptorelin Market size was valued at over USD 910 million in 2022. Driven by the growing occurrence of endometriosis across the global female population, industry is expected to grow at over 5% CAGR from 2023 to 2032. 


Triptorelin Market

To understand key trends  
Download Free Sample

Endometriosis is a disease that leads to scar tissue formation within the pelvis due to a chronic inflammatory response caused by the presence of endometrium outside the uterus. As per estimates, around 176 million women across the globe, around one in ten, suffer from endometriosis in their reproductive years, typically between the ages of 15 and 49. Triptorelin is efficacious in alleviating the pain symptoms caused by endometriosis. It has a favorable safety profile and has also been shown to improve reproductive function. Subsequently, it is commonly used to treat deep infiltrating endometriosis (DIE) among women.


Steep prices of triptorelin drugs may hamper industry outlook

Despite an extensive customer pool, triptorelin market faces a major challenge in the form of the high manufacturing cost of triptorelin drugs, which translates into steep medication prices for customers. Given that the raw materials utilized are specific to the drug, the quality of raw materials used in drug development is crucial, which further elevates costs. Meanwhile, the complexity of triptorelin manufacturing process, which entails a wide range of biological or chemical processes, is also impeding product adoption by limiting product availability to those who can afford it.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for triptorelin held a valuation of over USD 910 million in 2022 and is projected to grow at over 5% CAGR from 2023 to 2032, on account of surging occurrence of endometriosis across the global female population.

The triptorelin market size from the intradermal segment is anticipated to grow at over 4.5% CAGR from 2023 to 2032, fueled by the growing number of hormone therapies performed annually across the globe.

Europe triptorelin business valuation is poised to surpass USD 370 million by 2032, owing to the growing prevalence of diseases such as cancer and endometriosis in the region, coupled with increasing government investments towards the health and well-being of its citizens.

Some of the major triptorelin industry contenders include Taj Pharmaceuticals Limited., Anhui Anke Bioengineering (Group) Co., Ltd., Biozenta Lifescience Pvt. Ltd, Azurity Pharmaceuticals, Inc., and Verity Pharmaceuticals Inc., among others.

Triptorelin Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 13
  • Tables & Figures: 373
  • Countries covered: 32
  • Pages: 320
 Download Free Sample